A compound of Formula or a stereoisomer or tautomeric form thereof, wherein: represents: X represents -(SO 2)- or a single bond, wherein, When X represents -(SO 2)-: R 4 is selected from the group consisting of -NR 5 R 6, C 1 -C 6 alkyl, and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 1 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of fluoro, C 1 -C 4 alkyloxy, OH, oxo, C 1 -C 4 alkyl, and cyclopropyl, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3 and C 1 -C 3 alkyl and cyclopropyl; When X represents a single bond: R 4 is -C(=O)O-R 7, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl and cyclopropyl, such that at least one of R 1, R 2 and R 3 is Fluoro, and one other of R 1, R 2 and R 3 is Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl or cyclopropyl; R 5 is Hydrogen or methyl; R 6 is selected from the group consisting of C 1 -C 6 alkyl and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 1 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of fluoro, CN, OH, oxo, -NHC(=O)O-C 1 -C 4 alkyl, C 1 -C 4 alkyl optionally substituted with R 8, C 1 -C 4 alkyloxy, R 7 is selected from the group consisting of C 1 -C 6 alkyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; R 8 is selected from the group consisting OH, C 1 -C 4 alkyl and CN; or a pharmaceutically acceptable salt or a solvate thereof X represents -(SO 2)- or a single bond, wherein, When X represents -(SO 2)-: R 4 is selected from the group consisting of -NR 5 R 6, C 1 -C 6 alkyl, and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 1 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of fluoro, C 1 -C 4 alkyloxy, OH, oxo, C 1 -C 4 alkyl, and cyclopropyl, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3 and C 1 -C 3 alkyl and cyclopropyl; R 4 is selected from the group consisting of -NR 5 R 6, C 1 -C 6 alkyl, and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 1 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of fluoro, C 1 -C 4 alkyloxy, OH, oxo, C 1 -C 4 alkyl, and cyclopropyl, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3 and C 1 -C 3 alkyl and cyclopropyl; When X represents a single bond: R 4 is -C(=O)O-R 7, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl and cyclopropyl, such that at least one of R 1, R 2 and R 3 is Fluoro, and one other of R 1, R 2 and R 3 is Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl or cyclopropyl; R 4 is -C(=O)O-R 7, and R 1, R 2 and R 3 are each independently selected from the group consisting of Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl and cyclopropyl, such that at least one of R 1, R 2 and R 3 is Fluoro, and one other of R 1, R 2 and R 3 is Hydrogen, Halogen, CN, CHF 2, CH 2 F, CF 3, C 1 -C 3 alkyl or cyclopropyl; R 5 is Hydrogen or methyl; R 6 is selected from the group consisting of C 1 -C 6 alkyl and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 1 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of fluoro, CN, OH, oxo, -NHC(=O)O-C 1 -C 4 alkyl, C 1 -C 4 alkyl optionally substituted with R 8, C 1 -C 4 alkyloxy, R 7 is selected from the group consisting of C 1 -C 6 alkyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; R 8 is selected from the group consisting OH, C 1 -C 4 alkyl and CN; or a pharmaceutically acceptable salt or a solvate thereof